Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial.
Pfister C, Harter V, Allory Y, Radvanyi F, Culine S; VESPER Trial Investigators. Pfister C, et al. Among authors: culine s. Contemp Clin Trials Commun. 2020 Jan 30;17:100536. doi: 10.1016/j.conctc.2020.100536. eCollection 2020 Mar. Contemp Clin Trials Commun. 2020. PMID: 32083220 Free PMC article.
Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life.
Ploussard G, Paule B, Salomon L, Allory Y, Terry S, Vordos D, Hoznek A, Vacherot F, Abbou CC, Culine S, de la Taille A. Ploussard G, et al. Among authors: culine s. Prostate Cancer Prostatic Dis. 2010 Mar;13(1):97-101. doi: 10.1038/pcan.2009.51. Epub 2009 Nov 24. Prostate Cancer Prostatic Dis. 2010. PMID: 19935771 Free PMC article. Clinical Trial.
[Chemotherapy in perioperative setting for infiltrative bladder cancer].
Houédé N, Beuzeboc P, Culine S, Soulié M, Pfister C; Groupe vessie du Comité de cancérologie de l’Association française d’urologie. Houédé N, et al. Among authors: culine s. Prog Urol. 2012 Mar;22(3):139-45. doi: 10.1016/j.purol.2011.09.010. Epub 2011 Oct 28. Prog Urol. 2012. PMID: 22364623 Review. French.
Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.
Oudard S, Culine S, Vano Y, Goldwasser F, Théodore C, Nguyen T, Voog E, Banu E, Vieillefond A, Priou F, Deplanque G, Gravis G, Ravaud A, Vannetzel JM, Machiels JP, Muracciole X, Pichon MF, Bay JO, Elaidi R, Teghom C, Radvanyi F, Beuzeboc P. Oudard S, et al. Among authors: culine s. Eur J Cancer. 2015 Jan;51(1):45-54. doi: 10.1016/j.ejca.2014.10.009. Epub 2014 Nov 15. Eur J Cancer. 2015. PMID: 25459391 Clinical Trial.
[Castration modalities in prostate cancer: Are they all equal?].
Ploussard G, Bruyère F, Culine S, de La Taille A, Hennequin C, Oudard S, Pfister C, Ravery V, Salomon L. Ploussard G, et al. Among authors: culine s. Prog Urol. 2016 Apr;26(5):319-28. doi: 10.1016/j.purol.2016.02.010. Epub 2016 Mar 23. Prog Urol. 2016. PMID: 27017327 Review. French.
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW. Pouessel D, et al. Among authors: culine s. Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18. Ann Oncol. 2016. PMID: 27091807 Free PMC article.
Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort.
Pouessel D, Bastuji-Garin S, Houédé N, Vordos D, Loriot Y, Chevreau C, Sevin E, Beuzeboc P, Taille A, Le Thuaut A, Allory Y, Culine S. Pouessel D, et al. Among authors: culine s. Clin Genitourin Cancer. 2017 Feb;15(1):e45-e52. doi: 10.1016/j.clgc.2016.07.012. Epub 2016 Jul 21. Clin Genitourin Cancer. 2017. PMID: 27554584
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
Colomba E, Le Teuff G, Eisen T, Stewart GD, Fife K, Larkin J, Biondo A, Pickering L, Srinivasan A, Boyle H, Derosa L, Sternberg CN, Recine F, Ralph C, Saldana C, Barthélémy P, Bernhard JC, Gurney H, Verhoest G, Vauleon E, Bigot P, Berger J, Pfister C, Gravis G, Rodier JM, Culine S, Caty A, Rolland F, Priou F, Escudier B, Albiges L. Colomba E, et al. Among authors: culine s. Eur J Cancer. 2017 Jul;80:55-62. doi: 10.1016/j.ejca.2017.03.011. Epub 2017 May 23. Eur J Cancer. 2017. PMID: 28549248 Free article.
433 results